BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,373 | -33.2% | 11,917 | -33.6% | 0.00% | – |
| Q2 2023 | $126,262 | -0.7% | 17,935 | +17.6% | 0.00% | – |
| Q1 2023 | $127,160 | -9.4% | 15,247 | +24.8% | 0.00% | – |
| Q4 2022 | $140,286 | +15.0% | 12,220 | +26.0% | 0.00% | – |
| Q3 2022 | $122,000 | +139.2% | 9,700 | +102.8% | 0.00% | – |
| Q2 2022 | $51,000 | -13.6% | 4,783 | +30.3% | 0.00% | – |
| Q1 2022 | $59,000 | -16.9% | 3,672 | -29.1% | 0.00% | – |
| Q4 2021 | $71,000 | +7000.0% | 5,178 | +5718.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 89 | -13.6% | 0.00% | – |
| Q4 2017 | $1,000 | 0.0% | 103 | -65.8% | 0.00% | – |
| Q2 2016 | $1,000 | 0.0% | 301 | -3.8% | 0.00% | – |
| Q1 2016 | $1,000 | 0.0% | 313 | +172.2% | 0.00% | – |
| Q4 2015 | $1,000 | – | 115 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |